pentobarbital will lower the extent or result of elbasvir/grazoprevir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. The therapeutic influence of elbasvir/grazoprevir could possibly be reduced if coadministered with powerful CYP3A inducers and is also therefore contraindi